Preliminary experience with dosimetry, response and patient reported outcome after (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer

Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen (PSMA). We aimed to evaluate dosimetry, safety and efficacy of (177)Lu-PSMA-617 radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC). Fifteen patients each received two...

Descripción completa

Detalles Bibliográficos
Autores principales: Fendler, Wolfgang P., Reinhardt, Svenja, Ilhan, Harun, Delker, Andreas, Böning, Guido, Gildehaus, Franz J., Stief, Christian, Bartenstein, Peter, Gratzke, Christian, Lehner, Sebastian, Rominger, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356905/
https://www.ncbi.nlm.nih.gov/pubmed/27683041
http://dx.doi.org/10.18632/oncotarget.12240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356905/
https://www.ncbi.nlm.nih.gov/pubmed/27683041
http://dx.doi.org/10.18632/oncotarget.12240

Ejemplares similares